Retinal Disorders News Today

Pending trial results supporting prescribers’ efficacy and safety demands, gene therapies are poised to capture upwards of one-fifth of the AMD, GA and DME...

Regulated Information Leuven, BELGIUM, Boston, MA, US – October 30, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on October 27, 2023, from Atlas Spe...

EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 5 of funding under the Subscription Agreement with Atlas Special Opportunities LL...

EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 5 of funding under the Subscription Agreement with Atlas Special Opportunities LL...

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on September 14, 2023, from Atlas...

There are at least ten ongoing clinical trials for stem cell therapies in vision loss. We will delve into one of the preclinical studies in this piece.

Ophthalmic Drugs Market– Global Outlook and Forecast 2023-2030 is latest research study released by Allied Market Research evaluating the market risk side analysis, highlighting opportunities and leveraged with strategic and tactical decision-making support (2023-2030). The market Study is segmented by key a region...

Ophthalmic Drugs Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032 The Business Research Companys Ophthalmi

Stem cell therapies have been making significant progress in restoring vision loss. Here we describe recent advances that use CRISPR to treat retinitis pigmentosa.

CHICAGO (PRWEB) May 09, 2023 -- Prevent Blindness, the nation’s leading nonprofit eye health and safety organization, has declared May 15-21, 2023, as the